Paper26536664
Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ and 8 others. Oncotarget, 2015. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. Papers, record 26536664. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26536664
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal | Major topic |
| GPI-Linked Proteins | Major topic |
| Immunoconjugates | Major topic |
| Pancreatic Neoplasms | Major topic |
| Animals | |
| Benzenesulfonates | |
| Cell Line, Tumor | |
| Cytoplasm | |
| Humans | |
| Immunohistochemistry | |
| Indoles | |
| Male | |
| Mesothelin | |
| Mice, Inbred BALB C | |
| Mice, Nude | |
| Microscopy, Fluorescence | |
| Positron-Emission Tomography | |
| Radioisotopes | |
| Time Factors | |
| Tissue Distribution | |
| Transplantation, Heterologous | |
| Zirconium |
Source PubMed
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19443585 | Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. | J Nucl Med | 2009 | https://conductscience.org/library/papers/19443585 | PubMed |
| 2 | 20346868 | Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. | Nucl Med Biol | 2010 | https://conductscience.org/library/papers/20346868 | PubMed |
| 3 | 20072072 | Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model. | Nucl Med Commun | 2010 | https://conductscience.org/library/papers/20072072 | PubMed |
| 4 | 20357763 | Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. | Clin Pharmacol Ther | 2010 | https://conductscience.org/library/papers/20357763 | PubMed |
| 5 | 20395337 | 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. | J Nucl Med | 2010 | https://conductscience.org/library/papers/20395337 | PubMed |
| 6 | 21718943 | In vivo biodistribution and accumulation of 89Zr in mice. | Nucl Med Biol | 2011 | https://conductscience.org/library/papers/21718943 | PubMed |
| 7 | 21990576 | Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. | J Nucl Med | 2011 | https://conductscience.org/library/papers/21990576 | PubMed |
| 8 | 22072706 | PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. | J Nucl Med | 2011 | https://conductscience.org/library/papers/22072706 | PubMed |
| 9 | 22759592 | Emerging frontiers in pancreatic cancer research: elaboration of key genes, cells and the extracellular milieu. | Curr Opin Gastroenterol | 2012 | https://conductscience.org/library/papers/22759592 | PubMed |
| 10 | 22896693 | The pancreas cancer microenvironment. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22896693 | PubMed |
| 11 | 23096166 | PET/CT of cancer patients: part 1, pancreatic neoplasms. | AJR Am J Roentgenol | 2012 | https://conductscience.org/library/papers/23096166 | PubMed |
| 12 | 23062948 | ImmunoPET imaging of phosphatidylserine in pro-apoptotic therapy treated tumor models. | Nucl Med Biol | 2013 | https://conductscience.org/library/papers/23062948 | PubMed |
| 13 | 24154601 | Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. | Sci Transl Med | 2013 | https://conductscience.org/library/papers/24154601 | PubMed |
| 14 | 24989332 | Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. | Cancer | 2014 | https://conductscience.org/library/papers/24989332 | PubMed |
| 15 | 25453051 | Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET. | J Nucl Med | 2014 | https://conductscience.org/library/papers/25453051 | PubMed |
| 16 | 25756664 | Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. | Oncotarget | 2015 | https://conductscience.org/library/papers/25756664 | PubMed |
| 17 | 26172299 | Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types. | Oncotarget | 2015 | https://conductscience.org/library/papers/26172299 | PubMed |
| 18 | 26823490 | Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. | Mol Cancer Ther | 2016 | https://conductscience.org/library/papers/26823490 | PubMed |
| 19 | 11751476 | Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). | Clin Cancer Res | 2001 | https://conductscience.org/library/papers/11751476 | PubMed |
| 20 | 12827615 | Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. | Hum Pathol | 2003 | https://conductscience.org/library/papers/12827615 | PubMed |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42638115 | Immuno-PET imaging of mesothelin in ovarian cancer with 68Ga-XH04: a first-in-human study. | Biomark Res | 2026 | https://conductscience.org/library/papers/42638115 | PubMed |
| 42319928 | Universal diseased-site targeting via glycolysis-driven lactic acid gradient. | Sci Adv | 2026 | https://conductscience.org/library/papers/42319928 | PubMed |
| 41994562 | Mesothelin biology and the evolving landscape of targeted immunotherapy. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/41994562 | PubMed |
| 36348391 | Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy. | Exp Hematol Oncol | 2022 | https://conductscience.org/library/papers/36348391 | PubMed |
| 34203923 | Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine? | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34203923 | PubMed |
| 33327644 | Analytical Methods for the Detection and Quantification of ADCs in Biological Matrices. | Pharmaceuticals (Basel) | 2020 | https://conductscience.org/library/papers/33327644 | PubMed |
| 33106429 | Harnessing 64Cu/67Cu for a theranostic approach to pretargeted radioimmunotherapy. | Proc Natl Acad Sci U S A | 2020 | https://conductscience.org/library/papers/33106429 | PubMed |
| 32517181 | From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32517181 | PubMed |
| 32235331 | Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32235331 | PubMed |
| 31658755 | 99mTc-A1 as a Novel Imaging Agent Targeting Mesothelin-Expressing Pancreatic Ductal Adenocarcinoma. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31658755 | PubMed |
| 31057683 | Progress of Coordination and Utilization of Zirconium-89 for Positron Emission Tomography (PET) Studies. | Nucl Med Mol Imaging | 2019 | https://conductscience.org/library/papers/31057683 | PubMed |
| 30541081 | In Vivo Imaging With Confirmation by Histopathology for Increased Rigor and Reproducibility in Translational Research: A Review of Examples, Options, and Resources. | ILAR J | 2018 | https://conductscience.org/library/papers/30541081 | PubMed |
| 30370812 | Application of Immuno-PET in Antibody-Drug Conjugate Development. | Mol Imaging | 2018 | https://conductscience.org/library/papers/30370812 | PubMed |
| 29656320 | The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. | Target Oncol | 2018 | https://conductscience.org/library/papers/29656320 | PubMed |
| 28915667 | Assessment of near-infrared fluorophores to study the biodistribution and tumor targeting of an IL13 receptor α2 antibody by fluorescence molecular tomography. | Oncotarget | 2017 | https://conductscience.org/library/papers/28915667 | PubMed |
| 28638489 | Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. | Theranostics | 2017 | https://conductscience.org/library/papers/28638489 | PubMed |
| 28303026 | Strategies and challenges for the next generation of antibody-drug conjugates. | Nat Rev Drug Discov | 2017 | https://conductscience.org/library/papers/28303026 | PubMed |
| 27252651 | Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? | Front Pharmacol | 2016 | https://conductscience.org/library/papers/27252651 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MSLN | 10232 | PubTator's text mining | https://conductscience.org/library/genes/10232 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26536664
GET https://conductscience.org/api/papers/v1/26536664/references?page=2